CARBON REDUCTION PLAN

Inomed Health Limited

PPN 006 / NHS Carbon Reduction Plan

FY2025/26 | REPORTING PERIOD 1 APRIL 2025 - 31 MARCH 2026

Document field	Details
Supplier	Inomed Health Limited
Reporting entity	Inomed Health Limited (contracting entity)
Operational boundary	All operations of Inomed Health Limited. The company currently operates in the United Kingdom; therefore the UK boundary represents the company-wide/global operational boundary.
Reporting period	1 April 2025 to 31 March 2026 (current formal GHG reporting period)
Baseline year	2025/26 - first formal reporting period used as the baseline for this Carbon Reduction Plan.
Public publication date	10 August 2026 - planned public release via unrestricted read-only SharePoint link while the corporate website is temporarily unavailable.
Review frequency	At least annually, normally within six months of financial year end.

PUBLIC SUPPLIER DOCUMENT • PPN 006 / NHS PROCUREMENT SUPPORTING EVIDENCE

Commitment to achieving Net Zero

Inomed Health Limited is committed to achieving Net Zero greenhouse gas emissions by 2050 at the latest. This commitment applies to the whole reporting entity and its current global operational footprint. The company will prioritise absolute emissions reductions and will only consider neutralisation of residual, unavoidable emissions in the target year using credible, recognised approaches.

Governance and approval

Responsibility for this Carbon Reduction Plan sits with senior management. The Plan, targets and reported emissions are to be approved by a Director before publication and are reviewed at least annually as data quality and organisational activity change.

Baseline emissions footprint

This is Inomed Health Limited's first formal GHG emissions reporting cycle prepared to the PPN 006 structure. The company has established FY2025/26 (1 April 2025 to 31 March 2026) as its baseline period for future year-on-year comparison.

Data quality and leased-premises limitation

Inomed Health Limited occupies leased serviced-office premises. The landlord controls utility supply and invoices utilities through a fixed service charge rather than tenant-metered consumption. For this first formal baseline, the available building-level meter movements have therefore been converted into a documented screening estimate: partial-period electricity and gas readings have been annualised and an equal 1/40 office-space allocation has been applied because the centre publicly reports 40 office spaces. This is an estimation method, not a claim of verified tenant consumption, and will be replaced by a better floor-area, landlord or invoice allocation if available.

Emission source	2025/26 baseline position	Treatment in this Plan
Scope 1 - company-controlled vehicle (provisional classification)	Approx. 1.20 tCO2e. Current FY2025/26 internal mileage register labels YL73 NZZ as a Company vehicle. 4,588 total miles (3,363 business + 1,225 personal) are conservatively treated as managed/company-controlled vehicle activity pending ownership/control confirmation.	Screening method: 4,588 total FY2025/26 miles x 2025 UK Government average petrol managed-asset/passenger-vehicle factor (~0.26187 kgCO2e/mile). If the vehicle is confirmed private, reclassify business mileage to Scope 3 Category 6 and restate consistently.
Scope 2 - purchased electricity	Approx. 0.10 tCO2e location-based.	9,304 kWh whole-centre electricity movement annualised, then 1/40 office-space allocation, x 0.177 kgCO2e/kWh (2025 UK factor).
Scope 3 - upstream transport and distribution	Approx. 1.50 tCO2e screening estimate.	Relevant to imported/manufacturer medical-device supply. Replace with carrier shipment/weight/distance data.
Scope 3 - waste generated in operations	Approx. 0.06 tCO2e screening estimate.	Small-office/FTE benchmark because landlord waste reports are unavailable.
Scope 3 - business travel	0.00 tCO2e for recorded road travel under the current company-vehicle classification.	FY2025/26 recorded road mileage is currently classified in Scope 1 because the internal register labels YL73 NZZ as a company vehicle. Reclassify business mileage here if ownership/control is confirmed to be private.
Scope 3 - employee commuting	Approx. 0.53 tCO2e screening estimate.	2 employees x 1,007 average annual commuting miles/person x average petrol-car factor; conservative all-car assumption.
Scope 3 - downstream transport and distribution	Approx. 1.00 tCO2e screening estimate.	Third-party courier/distribution allowance pending carrier data.

Estimation note: the FY2025/26 baseline is reported as approximately 50.49 tCO2e. The figure combines measured/internal activity where available with transparent screening estimates for shared premises, commuting, purchased goods and logistics. The current internal mileage register labels YL73 NZZ as a company vehicle, so its recorded FY2025/26 road mileage is conservatively classified in Scope 1 pending final ownership/control confirmation. The estimates are not independently verified and will be refined as primary data improves.

Emissions	FY2025/26 estimated baseline (tCO2e)
Scope 1	1.20
Scope 2 (location-based)	0.10
Scope 3 - all relevant categories	49.19
Total emissions	50.49

Current emissions reporting

FY2025/26 is the initial formal baseline/reporting period. Estimated company-wide greenhouse gas emissions are 50.49 tCO2e, comprising Scope 1 of 1.20 tCO2e, Scope 2 of 0.10 tCO2e and Scope 3 of 49.19 tCO2e. All 15 GHG Protocol Scope 3 categories have been screened; all categories assessed as relevant are included in the reported Scope 3 total using activity data or an explicitly disclosed screening estimate. Future annual Plans will replace estimates with primary data wherever reasonably obtainable.

Scope 3 category screening - FY2025/26

Total estimated Scope 3 emissions: 49.19 tCO2e. Figures below are a first-cycle screening inventory. Values shown as 0.00 are categories screened as not relevant/not material or activity captured in another scope; estimated values are explicitly identified for future refinement.

GHG Protocol Scope 3 category	tCO2e	FY2025/26 method / rationale
1. Purchased goods and services	45.00	Relevant. First-cycle screening estimate. Prior reported turnover of £150,000 is used temporarily as a conservative spend envelope with a 0.30 kgCO2e/£ proxy. Replace with FY2025/26 supplier-spend data when available.
2. Capital goods	0.00	Not material / screened. No material FY2025/26 capital purchases identified in the evidence reviewed. Reassess against final accounts.
3. Fuel- and energy-related activities	0.25	Relevant. Screening allowance for upstream/WTT emissions associated with company-controlled road fuel plus estimated serviced-office energy.
4. Upstream transportation and distribution	1.50	Relevant. Screening allowance for manufacturer/import logistics pending carrier shipment, mass and distance data.
5. Waste generated in operations	0.06	Relevant. Small-office screening estimate for two staff; landlord waste reports are unavailable.
6. Business travel	0.00	Relevant - captured in Scope 1 vehicle. Recorded FY2025/26 road travel is treated as Scope 1 because the current internal register labels YL73 NZZ as a company vehicle. Reclassify here if ownership/control is confirmed to be private.
7. Employee commuting	0.53	Relevant. Screening estimate for two employees using a conservative car-commuting benchmark. Replace with employee survey data.

GHG Protocol Scope 3 category	tCO2e	FY2025/26 method / rationale
8. Upstream leased assets	0.10	Relevant. Landlord-controlled heating/gas screening estimate using whole-centre data and an office-space allocation proxy.
9. Downstream transportation and distribution	1.00	Relevant. Screening allowance for third-party courier/distribution activity pending carrier data.
10. Processing of sold products	0.00	Not relevant. Inomed distributes finished medical devices; no material downstream industrial processing identified.
11. Use of sold products	0.00	Not material / screened. No material customer energy use identified for the currently distributed product portfolio on available evidence.
12. End-of-life treatment of sold products	0.75	Relevant. Screening allowance for packaging and product end-of-life pending product mass/composition and disposal data.
13. Downstream leased assets	0.00	Not relevant. No downstream leased assets identified.
14. Franchises	0.00	Not relevant. No franchise operations identified.
15. Investments	0.00	Not relevant. No investment portfolio giving rise to financed-emissions reporting identified.

Emissions reduction targets

Inomed Health Limited has adopted a company-wide Net Zero target of 2050 at the latest, covering Scope 1, Scope 2 and all relevant Scope 3 emissions. Against the estimated FY2025/26 baseline of 50.49 tCO2e, the pathway is to reduce gross emissions by at least 20% by 2030, 40% by 2035, 60% by 2040, 80% by 2045 and at least 90% by 2050. No more than the residual 10% (5.05 tCO2e on the current baseline) would be neutralised in the target year using credible, recognised approaches. Progress will be reviewed annually.

Target year / milestone	Gross emissions target and commitment
FY2025/26 baseline	50.49 tCO2e - estimated baseline (0% reduction).
2030	40.39 tCO2e - 20% gross reduction target.
2035	30.29 tCO2e - 40% gross reduction target.
2040	20.20 tCO2e - 60% gross reduction target.
2045	10.10 tCO2e - 80% gross reduction target.
2050	5.05 tCO2e - 90% gross reduction target.

Graphical emissions pathway

Target pathway against the estimated FY2025/26 baseline of 50.49 tCO2e. Future annual CRPs will add actual reported results alongside this target line.



2050 endpoint: at least 90% gross absolute reduction (approximately 5.05 tCO2e residual on the current baseline), with no more than the residual 10% neutralised to reach Net Zero. The chart shows the gross-emissions reduction pathway before any target-year neutralisation.

Carbon reduction projects and environmental management measures

- Manage and reduce direct vehicle emissions from the company-controlled vehicle provisionally identified in the FY2025/26 mileage register, while confirming ownership/control and considering lower-emission alternatives at replacement.
- Use digital documentation, remote communication and virtual meetings where clinically and commercially appropriate to reduce avoidable travel and paper use.
- Engage landlords and premises managers to obtain the best available utility data and document limitations where tenant-specific data is unavailable.
- Strengthen supplier due diligence and engagement, including environmental expectations alongside modern-slavery and quality requirements.
- Review packaging, product distribution and logistics opportunities with manufacturers and freight providers, focusing on material efficiency and shipment consolidation where operationally appropriate.
- Develop product carbon-footprinting capability in advance of future NHS product-level carbon-footprint requirements.
- Continue development of the management system and governance framework so sustainability objectives, risks and actions are reviewed by senior management.

Future carbon reduction initiatives

- Complete annual Scope 1, Scope 2 and relevant Scope 3 measurement using the UK Government GHG Conversion Factors applicable to each reporting year.
- Introduce a documented employee commuting and business-travel data capture process.
- Obtain annual courier, freight and distribution activity data and use it to measure upstream and downstream transportation emissions.
- Introduce supplier sustainability questions for key manufacturers and logistics partners and track completion as a management KPI.
- Establish a documented approach for rented-premises emissions where direct tenant utility data is unavailable, using a defensible allocation or estimation method.

- Review opportunities for lower-carbon distribution, reduced packaging and recyclable materials in collaboration with manufacturers and NHS customers.
- Publish and review the Carbon Reduction Plan at least annually.

Reporting methodology

The Plan is structured in line with PPN 006 and NHS Carbon Reduction Plan requirements and uses GHG Protocol principles. For FY2025/26, all 15 Scope 3 categories have been screened to support the broader Evergreen Level 2 boundary of Scope 1, Scope 2 and all relevant Scope 3 emissions. UK Government 2025 greenhouse-gas conversion factors are used for electricity, gas and road travel where activity data is available; recognised government/industry benchmarks and clearly stated screening assumptions are used where primary data is unavailable.

Where primary activity data cannot reasonably be obtained, Inomed Health Limited uses a documented estimation method and retains the calculation basis. Estimates are clearly identified and are not described as verified data. The largest temporary estimate is purchased goods and services: the prior reporting-year £150,000 turnover figure is used only as a conservative expenditure envelope until the FY2025/26 supplier-spend ledger is available, with a rounded 0.30 kgCO2e/£ medical/precision-instruments supply-chain proxy. Freight, courier, waste, commuting and end-of-life figures are likewise screening estimates and will be replaced by primary data in future revisions.

Estimation sources and controls

Key sources used for the first-cycle estimate: internal FY2025/26 business mileage/vehicle register and fuel log; landlord EWIC meter-reading workbook and written confirmation; BSI Stage 1 report (two employees); NHS Evergreen prior company information (£150,000 turnover); UK Government GHG Conversion Factors 2025; Defra spend-based emissions multiplier guidance; Department for Transport commuting benchmarks; and landlord/public premises information. The vehicle register currently labels YL73 NZZ as a company vehicle; final ownership/control confirmation should be retained with the evidence file.

Declaration and sign-off

This Carbon Reduction Plan has been prepared for Inomed Health Limited. The company confirms its commitment to achieving Net Zero emissions by 2050 at the latest and to reviewing this Plan and its underlying emissions data at least annually.

Approval	Details
Director name	**Shazad Ali**
Role	**Director**
Signature	
Director approval date	9 August 2026
Approval status	For Director signature; public release planned 10 August 2026